These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 31621952)

  • 1. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
    Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
    Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization.
    Riviere MK; Yuan Y; Jourdan JH; Dubois F; Zohar S
    Stat Methods Med Res; 2018 Feb; 27(2):466-479. PubMed ID: 26988926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
    Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
    Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials.
    Guo B; Li D; Yuan Y
    Pharm Stat; 2018 Sep; 17(5):527-540. PubMed ID: 29882388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
    Takeda K; Taguri M; Morita S
    Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials.
    Yuan Y; Wu J; Gilbert MR
    Neurooncol Pract; 2021 Dec; 8(6):627-638. PubMed ID: 34777832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
    Wages NA; Tait C
    J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.
    Zang Y; Guo B; Qiu Y; Liu H; Opyrchal M; Lu X
    Clin Trials; 2024 Jun; 21(3):298-307. PubMed ID: 38205644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
    Koopmeiners JS; Modiano J
    Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
    Shimamura F; Hamada C; Matsui S; Hirakawa A
    J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials.
    Zhou Y; Lin R; Kuo YW; Lee JJ; Yuan Y
    JCO Clin Cancer Inform; 2021 Jan; 5():91-101. PubMed ID: 33439726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.
    Wang Z; Zhang J; Xia T; He R; Yan F
    J Biopharm Stat; 2024 Jul; 34(4):582-595. PubMed ID: 37461311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSNP: A two-stage nonparametric phase I/II clinical trial design for immunotherapy.
    Han Y; Liu H; Cao S; Zhang C; Zang Y
    Pharm Stat; 2021 Mar; 20(2):282-296. PubMed ID: 33025762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: a simulation study.
    Yamaguchi Y; Takeda K; Yoshida S; Maruo K
    J Biopharm Stat; 2024 May; 34(3):379-393. PubMed ID: 37114985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.